Hooftman Leon
Hooftman Leon, CMO, reported a transaction classified as return at Barinthus Biotherapeutics plc. involving 195166.000000 shares for an estimated $0.00. Reported holdings after the transaction were 0.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Sep 09, 2026
- Filing date
- Sep 09, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
BRNS price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- return Code D
- Identifier
- 0001104659-26-106338 Share Option (Right to Buy)
- Transaction date
- Sep 09, 2026 Filed Sep 09, 2026, 08:19 PM · 0d delay
- Shares
- 195,166 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 0 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-6 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 0
Filing reported within two business days of the transaction. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Chief Medical Officer
- F1
The Ordinary Shares may be represented by American Depositary Shares ("ADSs" and together with the Ordinary Shares, the "Shares"), each of which currently represents one Ordinary Share.
- F2
This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the "Merger Agreement") by and among the Issuer, Beacon Topco, Inc.…
- F3
Represents restricted share units ("RSUs") previously granted to the Reporting Person, vesting of which was subject to completion of the transactions contemplated by the Merger Agreement. Each RSU rep…
- F4
Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to repr…
0 other transactions
0 recent txs